Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia

BACKGROUND: 5-Azacitidine administered as a 7-day dosing regimen (7–0-0) is approved in high risk IPSS myelodysplastic syndrome (MDS) patients. Alternative regimens such as a 5-day (5–0-0) or 7-day with a weekend break (5–2-2) are commonly used. No randomized controlled trial has been done directly...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Roman M., Lazo-Langner, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793426/
https://www.ncbi.nlm.nih.gov/pubmed/29435331
http://dx.doi.org/10.1186/s12878-017-0094-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793426/
https://www.ncbi.nlm.nih.gov/pubmed/29435331
http://dx.doi.org/10.1186/s12878-017-0094-8

Ejemplares similares